PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
32.15%
Cash & equivalents growing 32.15% while AVXL's declined -5.55%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
32.15%
Below half of AVXL's -5.55%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.78%
Below half of AVXL's -4.03%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-2.88%
Below half AVXL's -100.00%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.86%
Below half of AVXL's 10254.94%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
30.51%
Below half of AVXL's -3.51%. Michael Burry sees a potential red flag for stagnation or capital shortage.
63.16%
1.1-1.25x AVXL's 51.03%. Bill Ackman wonders if the firm relies on extended payables to manage cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.70%
Less than half of AVXL's 160.04%. David Dodd sees fewer expansions in other current obligations.
49.30%
Similar yoy to AVXL's 46.86%. Walter Schloss sees parallel short-term liability strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.30%
Similar yoy to AVXL's 46.83%. Walter Schloss sees parallel expansions in total liabilities.
16.87%
Above 1.5x AVXL's 1.28%. Michael Burry suspects heavy new equity expansion or dilution.
-5.16%
0.5-0.75x AVXL's -9.11%. Martin Whitman is wary of weaker retention or lower profitability.
-13.18%
Higher AOCI Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
26.52%
Below half AVXL's -17.77%. Michael Burry sees potential underperformance in building shareholder capital.
30.51%
Below half AVXL's -3.51%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-32.15%
Less than half of AVXL's 4.69%. David Dodd sees better deleveraging or stronger cash buildup than competitor.